panitumumab,bevacizumab
takeda,amgen,roche
['paradigm', 'panitumumab']
i have to admit, i am underimpressed with paradigm trial. is difference clinically meaningful? os curves overlap &amp; cross. no improvement in pfs. 10 treatment-related deaths in panitumumab arm. all pts are ras wt, why only half got antiegfr upon progression in the bev arm? #asco22
Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet ? endorsement - will summarize oncology news in one tweet each